Court Grants Teva Summary Judgment Of Non-Infringement On Eloxatin
Teva Pharmaceutical Industries Ltd. announced that the U.S. District Court for the District of New Jersey has granted summary judgment in Teva's favor on the issue of non-infringement with regard to Debiopharm's U.S. Patent No. 5,338,874. The patent is listed in the Orange Book for Sanofi-Aventis' chemotherapy medication Eloxatin, which had annual sales of approximately $1.3 billion in the United States for the twelve months that ended December 2008, based on IMS sales data. [more...]
|
|
|
